Beranda › Kanker Payudara › Montana
Uji klinis Kanker Payudara di Montana
13 studi untuk Kanker Payudara mencari peserta di lokasi di Montana.
Kota di Montana
Teks studi resmi (Bahasa Inggris)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Intermountain Healthcare, Billings
Menerima pesertaFase 3
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- dan 7 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07007559Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06797635A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute), Billings
Menerima pesertaFase 1
Usia 18 hingga 55 · Wanita · Diperbarui 9 Sep 2026 · NCT07310420Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
- dan 10 lainnya
Menerima pesertaFase 3
Usia 18 hingga 60 · Wanita · Diperbarui 2 Sep 2026 · NCT05879926Integrated Cancer Repository for Cancer Research
- Bozeman Health Deaconess Hospital, Bozeman
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- SCL Health - Cancer Centers of Montana, Billings
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT06757634De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- Benefis Sletten Cancer Institute, Great Falls
- dan 1 lainnya
Menerima pesertaFase 3
Usia 50 hingga 70 · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Montana Cancer Consortium NCORP, Billings
- dan 5 lainnya
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06418204Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
- University of Montana, Missoula
Menerima pesertaFase 2
Usia 18 hingga 89 · Semua jenis kelamin · Diperbarui 5 Feb 2026 · NCT07001241SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Billings
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Benefis Healthcare- Sletten Cancer Institute, Great Falls
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT03418961Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.